TheraCryf PLC

TCF

Company Profile

  • Business description

    TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.

  • Contact

    Congleton Road
    Alderley Park
    Nether AlderleyCheshireSK10 4TG
    GBR

    T: +44 1625315090

    E: [email protected]

    https://www.evgen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 March 2026

    Employees

    9

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.7048.800.56%
CAC 407,902.2523.790.30%
DAX 4024,456.8192.75-0.38%
Dow JONES (US)44,676.74218.440.49%
FTSE 1008,975.66108.641.23%
HKSE24,028.37136.050.57%
NASDAQ20,600.9210.42-0.05%
Nikkei 22539,646.36174.92-0.44%
NZX 50 Index12,760.208.41-0.07%
S&P 5006,275.2511.990.19%
S&P/ASX 2008,589.2050.600.59%
SSE Composite Index3,509.6816.630.48%

Market Movers